Skip to main content
Top
Published in: International Journal of Clinical Oncology 4/2016

01-08-2016 | Original Article

Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors

Authors: Terukazu Nakamura, Akihiro Kawauchi, Masakatsu Oishi, Takashi Ueda, Takumi Shiraishi, Hiroyuki Nakanishi, Kazumi Kamoi, Yoshio Naya, Fumiya Hongo, Koji Okihara, Tsuneharu Miki

Published in: International Journal of Clinical Oncology | Issue 4/2016

Login to get access

Abstract

Objective

To assess the efficacy, outcome and complications of post-chemotherapy laparoscopic retroperitoneal lymph node dissection (L-RPLND) for stage IIA/B testicular germ cell tumor (GCT) patients in comparison with open RPLND (O-RPLND).

Methods

L-RPLND was performed in 14 patients with stage IIA/B non-seminoma GCTs among 154 non-seminoma patients who received RPLND after completion of chemotherapy with tumor marker normalization at our institution between 1998 and 2013. Their outcomes were compared with those of 14 patients with stage IIA/B non-seminoma GCTs treated with O-RPLND during the same period. Clinical parameters were compared between L-RPLND and O-RPLND.

Results

There were no significant differences in the background characteristics of the two groups except for follow-up duration (36 months for L-RPLND, 70 months for O-RPLND; p = 0.02). Blood loss during surgery was significantly less for the L-RPLND group than for the O-RPLND group (155 mL for L-RPLND, 700 mL for O-RPLND; p < 0.001). Parameters related to post-operative recovery were significantly better for the L-RPLND group than for the O-RPLND group. Histopathological examination showed no difference between the two groups. Neither group had disease recurrence.

Conclusion

Post-chemotherapy L-RPLND with a bilateral template and nerve-sparing method was safe, effective, and showed a high preservation rate of antegrade ejaculation with no deterioration of outcomes compared to O-RPLND.
Literature
1.
go back to reference Guidelines on Testicular Cancer, European Association of Urology, 2012 Guidelines on Testicular Cancer, European Association of Urology, 2012
2.
go back to reference NCCN Clinical Practice Guidelines in Oncology, Testicular Cancer, 2012 NCCN Clinical Practice Guidelines in Oncology, Testicular Cancer, 2012
3.
go back to reference Klotz L (1994) Laparoscopic retroperitoneal lymphadenectomy for high-risk stage I nonseminomatous germ cell tumor: report of four cases. Urology 43:752–756CrossRefPubMed Klotz L (1994) Laparoscopic retroperitoneal lymphadenectomy for high-risk stage I nonseminomatous germ cell tumor: report of four cases. Urology 43:752–756CrossRefPubMed
4.
go back to reference Janetschek G, Reissigl A, Peschel R et al (1994) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular tumor. Urology 44:382–391CrossRefPubMed Janetschek G, Reissigl A, Peschel R et al (1994) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular tumor. Urology 44:382–391CrossRefPubMed
5.
go back to reference Palese MA, Su LM, Kavoussi LR (2002) Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology 60:130–134CrossRefPubMed Palese MA, Su LM, Kavoussi LR (2002) Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology 60:130–134CrossRefPubMed
6.
go back to reference Maldonado-Valadez R, Schilling D, Anastasiadis AG et al (2007) Post-chemotherapy laparoscopic retroperitoneal lymph-node dissection in testis cancer patients. J Endourol 21:1501–1504CrossRefPubMed Maldonado-Valadez R, Schilling D, Anastasiadis AG et al (2007) Post-chemotherapy laparoscopic retroperitoneal lymph-node dissection in testis cancer patients. J Endourol 21:1501–1504CrossRefPubMed
7.
go back to reference Arai Y, Kaiho Y, Yamada S, Saito H et al (2012) Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes. Int Urol Nephrol 44:1389–1395CrossRefPubMed Arai Y, Kaiho Y, Yamada S, Saito H et al (2012) Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes. Int Urol Nephrol 44:1389–1395CrossRefPubMed
8.
go back to reference Kimura Y, Nakamura T, Kawauchi A et al (2013) Post-chemotherapy nerve-sparing laparoscopic retroperitoneal lymph node dissection in stage IIB testicular cancer. Int J Urol 20:837–841CrossRefPubMed Kimura Y, Nakamura T, Kawauchi A et al (2013) Post-chemotherapy nerve-sparing laparoscopic retroperitoneal lymph node dissection in stage IIB testicular cancer. Int J Urol 20:837–841CrossRefPubMed
9.
go back to reference Calestroupat JP, Sanchez-Salas R, Cathelineau X et al (2009) Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor. J Endourol 23:645–650CrossRefPubMed Calestroupat JP, Sanchez-Salas R, Cathelineau X et al (2009) Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor. J Endourol 23:645–650CrossRefPubMed
10.
go back to reference Miki T, Mizutani Y, Nakamura T et al (2009) Post-chemotherapy nerve-sparing retroperitoneal lymph node dissection for advanced germ cell tumor. Int J Urol 16:379–382CrossRefPubMed Miki T, Mizutani Y, Nakamura T et al (2009) Post-chemotherapy nerve-sparing retroperitoneal lymph node dissection for advanced germ cell tumor. Int J Urol 16:379–382CrossRefPubMed
11.
go back to reference LeBlanc E, Caty A, Dargent D et al (2001) Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumors of the testis with introduction of a nerve sparing technique: description results. J Urol 165:89–92CrossRefPubMed LeBlanc E, Caty A, Dargent D et al (2001) Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumors of the testis with introduction of a nerve sparing technique: description results. J Urol 165:89–92CrossRefPubMed
12.
go back to reference Steiner H, Zangerl F, Sto¨hr B et al (2008) Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol 180:1348–1352CrossRefPubMed Steiner H, Zangerl F, Sto¨hr B et al (2008) Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol 180:1348–1352CrossRefPubMed
13.
go back to reference Steiner H, Leonhartsberger N, Stoehr B et al (2013) Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients. Eur Urol 63:1013–1017CrossRefPubMed Steiner H, Leonhartsberger N, Stoehr B et al (2013) Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients. Eur Urol 63:1013–1017CrossRefPubMed
14.
go back to reference Aufderklamm S, Todenhöfer T, Hennenlotter J et al (2013) Bilateral laparoscopic postchemotherapy retroperitoneal lymph-node dissection in nonseminomatous germ cell tumors—a comparison to template dissection. J Endourol 27:856–861CrossRefPubMed Aufderklamm S, Todenhöfer T, Hennenlotter J et al (2013) Bilateral laparoscopic postchemotherapy retroperitoneal lymph-node dissection in nonseminomatous germ cell tumors—a comparison to template dissection. J Endourol 27:856–861CrossRefPubMed
15.
go back to reference Kenney PA, Tuerk IA (2008) Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer. World J Urol 26:561–569CrossRefPubMed Kenney PA, Tuerk IA (2008) Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer. World J Urol 26:561–569CrossRefPubMed
16.
go back to reference International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594–603 International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594–603
17.
go back to reference Winter C, Pfister D, Busch J et al (2012) Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol 61:403–409CrossRefPubMed Winter C, Pfister D, Busch J et al (2012) Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol 61:403–409CrossRefPubMed
18.
go back to reference Steiner H, Peschel R, Janetschek G et al (2004) Long-term results of laparoscopic retroperinonael lymphnode dissection: a single-center 10-year experience. Urology 63:550–555CrossRefPubMed Steiner H, Peschel R, Janetschek G et al (2004) Long-term results of laparoscopic retroperinonael lymphnode dissection: a single-center 10-year experience. Urology 63:550–555CrossRefPubMed
19.
go back to reference Carver BS, Shayegan B, Eggener S et al (2007) Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 25:4365–4369CrossRefPubMed Carver BS, Shayegan B, Eggener S et al (2007) Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 25:4365–4369CrossRefPubMed
20.
go back to reference Beck SD, Foster RS, Bihrle R et al (2007) Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer 110:1235–1240CrossRefPubMed Beck SD, Foster RS, Bihrle R et al (2007) Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer 110:1235–1240CrossRefPubMed
21.
go back to reference Heidenreich A, Pfister D, Witthuhn R et al (2009) Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer:radical or modified template resection. Eur Urol 55:217–226CrossRefPubMed Heidenreich A, Pfister D, Witthuhn R et al (2009) Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer:radical or modified template resection. Eur Urol 55:217–226CrossRefPubMed
22.
go back to reference Vallier C, Savoie PH, Delpero JR et al (2014) External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer. World J Urol 32:1573–1578CrossRefPubMed Vallier C, Savoie PH, Delpero JR et al (2014) External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer. World J Urol 32:1573–1578CrossRefPubMed
23.
go back to reference Aufderklamm S, Todenhöfer T, Hennenlotter J et al. (2014) Postchemotherapy laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors infiltrating the great vessels. J Endourol 28:668–674CrossRefPubMed Aufderklamm S, Todenhöfer T, Hennenlotter J et al. (2014) Postchemotherapy laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors infiltrating the great vessels. J Endourol 28:668–674CrossRefPubMed
Metadata
Title
Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors
Authors
Terukazu Nakamura
Akihiro Kawauchi
Masakatsu Oishi
Takashi Ueda
Takumi Shiraishi
Hiroyuki Nakanishi
Kazumi Kamoi
Yoshio Naya
Fumiya Hongo
Koji Okihara
Tsuneharu Miki
Publication date
01-08-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0934-0

Other articles of this Issue 4/2016

International Journal of Clinical Oncology 4/2016 Go to the issue

Introduction to Invited Review Articles

Biological imaging in clinical oncology—introduction

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine